Midgley Rachel, Kerr David
Department of Clinical Pharmacology and Cancer Therapeutics, Racliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK.
Ann Oncol. 2005 Jul;16(7):999-1004. doi: 10.1093/annonc/mdi208. Epub 2005 Jun 6.
Angiogenesis is crucial to tumour initiation, survival and metastasis. Vascular endothelial growth factor (VEGF) is one of the most important pro-angiogenic factors in cancer development. Bevacizumab (a humanised monoclonal antibody against VEGF) has a reasonable safety profile and proven efficacy in a phase III trial in advanced colorectal cancer. Efficacy of Bevacizumab also looks promising in non small cell lung cancer, renal cancer and a variety of other solid tumours. Questions still surround optimal dosing and the appropriate selection of patients who are most likely to benefit. Future trials will address these questions and provide further translational insights.
血管生成对于肿瘤的起始、存活和转移至关重要。血管内皮生长因子（VEGF）是癌症发展过程中最重要的促血管生成因子之一。贝伐单抗（一种抗VEGF的人源化单克隆抗体）在晚期结直肠癌的III期试验中具有合理的安全性和已证实的疗效。贝伐单抗在非小细胞肺癌、肾癌和多种其他实体瘤中的疗效也看起来很有前景。关于最佳剂量以及最有可能受益的患者的适当选择仍存在疑问。未来的试验将解决这些问题并提供进一步的转化见解。
